Chronic hepatitis B affects around 250 million people in the world and its cure remains elusive. At the 2023 European Association for the Study of the Liver Congress in Vienna, Austria, Emily Harrison of Precision Biosciences Inc. presented the company’s work on using a naturally occurring endonuclease in the development of its ARCUS gene editing approach to eradicating the persistent viral infection.
Arvinas Operations Inc. and Genentech Inc. have described proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau (VHL) E3 ubiquitin ligase binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) targeting moiety through a linker reported to be useful for the treatment of cancer, including non-small-cell lung cancer.
St. Jude Children’s Research Hospital has divulged proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a tyrosine-protein kinase Lck targeting moiety via a linker acting as Lck degradation inducers reported to be useful for the treatment of cancer and immunological disorders.
Researchers at Centre National de la Recherche Scientifique, Université De Picardie Jules Verne and Université Paris-Est Créteil Val de Marne (UPEC) have identified lipid anionic oligosaccharides acting as microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of Alzheimer’s disease.
Benobio Co. Ltd. has synthesized novel quinizarin derivatives acting as bromodomain and extra-terminal (BET) protein inhibitors reported to be useful for the treatment of nonalcoholic fatty liver disease (NAFLD).
University of Western Australia has disclosed 3,4-methylenedioxymethamphetamine (MDMA) analogues acting as dopamine transporter (DAT) and/or norepinephrine transporter (NET) and/or serotonin transporter (SERT) modulators reported to be useful for the treatment of neurological and psychiatric disorders.
Researchers from Westlake Therapeutics (Hangzhou) Co. Ltd. have presented the discovery and preclinical evaluation of a novel erythrocyte-anti-PD-1 antibody conjugate, WTX-212, being developed for the treatment of cancer.
The family of 32 known RNA alphaviruses are present globally, are transmitted by mosquitos, and can cause human disease most commonly arthritogenic or encephalitic in presentation, the latter of which has a fatality rate as high as 35% to 75% depending on host co-morbidities. Previous studies have demonstrated antibody-mediated protection against specific types of alphavirus infections, but broad-spectrum protection against multiple alphavirus has only been reported recently. Even more, the vaccine-mediated elicitation of monoclonal antibodies (MAbs) has yet to be demonstrated until now.
Nephrodi Therapeutics Inc. has entered an agreement with The McQuade Center for Strategic Research and Development LLC (MSRD), a member of the Otsuka family of pharmaceutical companies, to collaborate on the clinical development of Nephrodi's NDI-5001 for X-linked congenital nephrogenic diabetes insipidus (NDI). NDI-5001 is a kidney-targeted small molecule AMPK activator.
RSS
